As of 2025-04-30, the Relative Valuation of Regenxbio Inc (RGNX) is (183.63) USD. This relative valuation is based on P/E multiples. With the latest stock price at 9.41 USD, the upside of Regenxbio Inc based on Relative Valuation is -2051.4%.
The range of the Relative Valuation is (171.73) - (184.42) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 37.9x - 51.8x | 44.8x |
| Forward P/E multiples | 31.7x - 40.7x | 36.2x |
| Fair Price | (171.73) - (184.42) | (183.63) |
| Upside | -1925.0% - -2059.8% | -2051.4% |
| Date | P/E |
| 2025-04-25 | -2.02 |
| 2025-04-24 | -2.03 |
| 2025-04-23 | -1.96 |
| 2025-04-22 | -1.73 |
| 2025-04-21 | -1.47 |
| 2025-04-17 | -1.31 |
| 2025-04-16 | -1.36 |
| 2025-04-15 | -1.45 |
| 2025-04-14 | -1.40 |
| 2025-04-11 | -1.30 |
| 2025-04-10 | -1.19 |
| 2025-04-09 | -1.30 |
| 2025-04-08 | -1.17 |
| 2025-04-07 | -1.31 |
| 2025-04-04 | -1.39 |
| 2025-04-03 | -1.47 |
| 2025-04-02 | -1.56 |
| 2025-04-01 | -1.49 |
| 2025-03-31 | -1.58 |
| 2025-03-28 | -1.73 |
| 2025-03-27 | -1.75 |
| 2025-03-26 | -1.81 |
| 2025-03-25 | -1.81 |
| 2025-03-24 | -1.92 |
| 2025-03-21 | -1.82 |
| 2025-03-20 | -1.85 |
| 2025-03-19 | -1.88 |
| 2025-03-18 | -1.72 |
| 2025-03-17 | -1.54 |
| 2025-03-14 | -1.48 |
| 2025-03-13 | -1.45 |
| 2025-03-12 | -1.47 |
| 2025-03-11 | -1.35 |
| 2025-03-10 | -1.33 |
| 2025-03-07 | -1.40 |
| 2025-03-06 | -1.42 |
| 2025-03-05 | -1.38 |
| 2025-03-04 | -1.31 |
| 2025-03-03 | -1.31 |
| 2025-02-28 | -1.45 |
| 2025-02-27 | -1.46 |
| 2025-02-26 | -1.47 |
| 2025-02-25 | -1.48 |
| 2025-02-24 | -1.53 |
| 2025-02-21 | -1.60 |
| 2025-02-20 | -1.62 |
| 2025-02-19 | -1.65 |
| 2025-02-18 | -1.67 |
| 2025-02-14 | -1.61 |
| 2025-02-13 | -1.62 |